LFWD icon

ReWalk Robotics

1.10 USD
-0.04
3.51%
At close Jun 13, 4:00 PM EDT
After hours
1.15
+0.05
4.55%
1 day
-3.51%
5 days
-9.09%
1 month
-22.54%
3 months
-31.25%
6 months
-33.33%
Year to date
-50.67%
1 year
-75.77%
5 years
-90.53%
10 years
-99.95%
 

About: Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.

Employees: 80

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

827% more call options, than puts

Call options by funds: $658K | Put options by funds: $71K

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

1.29% less ownership

Funds ownership: 3.05% [Q4 2024] → 1.76% (-1.29%) [Q1 2025]

30% less funds holding

Funds holding: 23 [Q4 2024] → 16 (-7) [Q1 2025]

31% less capital invested

Capital invested by funds: $465K [Q4 2024] → $319K (-$145K) [Q1 2025]

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Research analyst outlook

We haven’t received any recent analyst ratings for LFWD.

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
Lifeward Names Mark Grant as New CEO
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Names Mark Grant as New CEO
Neutral
GlobeNewsWire
3 weeks ago
Lifeward to Present at Sidoti Virtual Investor Conference on May 21
MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd.
Lifeward to Present at Sidoti Virtual Investor Conference on May 21
Negative
Zacks Investment Research
1 month ago
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.73 per share a year ago.
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
Neutral
Seeking Alpha
1 month ago
Lifeward Ltd. (LFWD) Q1 2025 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD ) Q1 2025 - Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Almog Adar - VP, Finance Conference Call Participants Yale Jen - Laidlaw and Company Swayampakula Ramakanth - H.
Lifeward Ltd. (LFWD) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Lifeward Ltd. Reports First Quarter 2025 Financial Results
U.S. pipeline of ReWalk opportunities continues to build with  over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15%  reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Ltd. Reports First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
Neutral
GlobeNewsWire
1 month ago
Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025.
Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025
Neutral
GlobeNewsWire
1 month ago
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the launch of the ReWalk 7 Personal Exoskeleton, which was released for sales in the U.S. earlier this month MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
Neutral
GlobeNewsWire
1 month ago
Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton
Positive
Zacks Investment Research
1 month ago
LFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7
Lifeward launches ReWalk 7 in the United States, offering advanced mobility, greater control and smarter walking for individuals with spinal cord injuries.
LFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7
Charts implemented using Lightweight Charts™